Poietis, a leading company in the blooming bioprinting industry, closed a €5 million Series A financing round to accelerate technological developments that could lead to the first implantation of a bioprinted tissue into patients from 2021. This successful operation has been carried out through a new crowdfunding fund- raising on WiSEED platform, the investment by the Nouvelle Aquitaine Co- investment Fund as well as granting of non-dilutive funding obtained as part of the Worldwide Innovation Challenge.
“We are proud of the confidence shown by our historical investors who have been with us almost since inception (WiSEED and business angels) and the investment by NACO. The funds will allow to respond to one of the main regenerative medicine challenges through the development of tissue manufacturing solutions based on bioprinting for clinical purpose”.
Fabien Guillemot, President and Chief Scientific Officer, Poietis.
Poietis has gained an internationally recognized position in the field of bioprinting by establishing partnerships with leading industrial groups such as BASF and L’Oréal. The company recently began commercializing its first commercially-available bioprinted tissue, announces the closing of a second round of financing. This €5m Series A round is taking place through a crowdfunding fund-raising round on the WiSEED platform, along with investment by the Nouvelle Aquitaine Co-investment Fund as well as granting of non-dilutive funding obtained in the framework of the Phase 2 of the worldwide Innovation Challenge (“personalized medicine” call).
Poietis is thus endowed with financial resources that will enable the company to accelerate its technological developments aimed at making its technology compatible with regulatory requirements and the Good Manufacturing Practices (GMP) for advanced therapy medicinal products (ATMPs). The goal will be to ensure the reproducibility, standardization and traceability of the tissue manufacturing process while ensuring the biological safety of bioprinted tissues. Consequently, bioprinted tissues could be implanted into patients from 2021.
Poietis expectation is to consolidate its leadership and to take a significant part of the 3D bioprinting market, estimated to reach nearly 800 million in 2022 and 2.5 billion in 2024.
“After having developed the skin bio-printing applications for the dermo-cosmetic industry, we will be able, thanks to this fundraising, to reinforce our activities into regenerative medicine and target other organs than skin, such as the liver, in collaboration with university hospital centers,” commented Bruno Brisson, Poietis co-founder and VP Business Development.
Louise Chopinet, Responsible of Health Projects at WiSEED, added that “for the second time we achieved a record collection on WiSEED with 1.1M € collected from 1029 private investors. A renewed success after a rst round of € 1M in 2015 thanks to the performance of the Poietis team in achieving its objectives, which guarantees the trust given by our investors. Poietis answers important challenges in the medical sector, and we are proud to support its development”. “NACO is very happy to be able to support a promising and job- creating regional start-up. This operation is fully in line with the Nouvelle Aquitaine Region’s strategy to support innovative companies,” concluded Bernard Estienne, Director of Aquiti Gestion, who runs the NACO (New Aquitaine Co- Investment) fund.